SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Nicola Ruth, Deirdre Kelly, A review of the long-term outlook of children and young people post liver transplant, Clinical Investigation, 2014, 4, 3, 235

    CrossRef

  2. 2
    Irene Shu, Angela M. Wright, Wayne L. Chandler, David W. Bernard, Ping Wang, Analytical Performance of QMS Everolimus Assay on Ortho Vitros 5,1 FS Fusion Analyzer, Therapeutic Drug Monitoring, 2014, 36, 2, 264

    CrossRef

  3. 3
    Daniel Nils Gotthardt, Helge Bruns, Karl Heinz Weiss, Peter Schemmer, Current strategies for immunosuppression following liver transplantation, Langenbeck's Archives of Surgery, 2014,

    CrossRef

  4. 4
    S. K. Asrani, R. H. Wiesner, J. F. Trotter, G. Klintmalm, E. Katz, E. Maller, J. Roberts, N. Kneteman, L. Teperman, J. J. Fung, J. M. Millis, De Novo Sirolimus and Reduced-Dose Tacrolimus Versus Standard-Dose Tacrolimus After Liver Transplantation: The 2000–2003 Phase II Prospective Randomized Trial, American Journal of Transplantation, 2014, 14, 2
  5. 5
    Lluís Castells, Carme Baliellas, Itxarone Bilbao, Carme Cantarell, Josep Maria Cruzado, Núria Esforzado, Juan Carlos García-Valdecasas, Laura Lladó, Antoni Rimola, Daniel Serón, Federico Oppenheimer, Detección precoz, prevención y manejo de la insuficiencia renal en el trasplante hepático, Gastroenterología y Hepatología, 2014,

    CrossRef

  6. 6
    M. Sterneck, G. M. Kaiser, N. Heyne, N. Richter, F. Rauchfuss, A. Pascher, P. Schemmer, L. Fischer, C. G. Klein, S. Nadalin, F. Lehner, U. Settmacher, P. Neuhaus, D. Gotthardt, M. Loss, S. Ladenburger, E. M. Paulus, M. Mertens, H. J. Schlitt, Everolimus and Early Calcineurin Inhibitor Withdrawal: 3-Year Results From a Randomized Trial in Liver Transplantation, American Journal of Transplantation, 2014, 14, 3
  7. 7
    Εvangelos Cholongitas, Ioannis Goulis, Eleni Theocharidou, Nikolaos Antoniadis, Ioannis Fouzas, Dimitrios Giakoustidis, George Imvrios, Olga Giouleme, Vasilios Papanikolaou, Evangelos Akriviadis, Themistoklis Vasiliadis, Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience, Hepatology International, 2014, 8, 1, 137

    CrossRef

  8. 8
    L.-B. Jeng, A. Thorat, Y.-W. Hsieh, H.-R. Yang, C.-C. Yeh, T.-H. Chen, S.-C. Hsu, C.-H. Hsu, Experience of Using Everolimus in the Early Stage of Living Donor Liver Transplantation, Transplantation Proceedings, 2014, 46, 3, 744

    CrossRef

  9. 9
    H. Jun, C.-W. Jung, M.-G. Kim, K.-T. Park, Experiences on Conversion to Once-Daily Advagraf and Sirolimus Combination in Stable Kidney Recipients, Transplantation Proceedings, 2014, 46, 2, 400

    CrossRef

  10. 10
    Michael R. Charlton, Improving Long-Term Outcomes After Liver Transplantation, Clinics in Liver Disease, 2014, 18, 3, 717

    CrossRef

  11. 11
    Manuel Rodríguez-Perálvarez, Manuel De la Mata, Andrew K. Burroughs, Liver transplantation, Current Opinion in Organ Transplantation, 2014, 19, 3, 253

    CrossRef

  12. 12
    Evangelos Cholongitas, Chrysanthi Mamou, Kryssia I. Rodríguez-Castro, Patrizia Burra, Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review, Transplant International, 2014, 27, 8
  13. 13
    Gabriel C. Oniscu, Geraldine Diaz, Josh Levitsky, Meeting report of the 19th Annual International Congress of the International Liver Transplantation Society (Sydney Convention and Exhibition Centre, Sydney, Australia, June 12-15, 2013), Liver Transplantation, 2014, 20, 1
  14. 14
    Hallvard Holdaas, Luciano Potena, Faouzi Saliba, mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?, Transplantation Reviews, 2014,

    CrossRef

  15. 15
    Bruce Kaplan, Yasir Qazi, Jason R. Wellen, Strategies for the management of adverse events associated with mTOR inhibitors, Transplantation Reviews, 2014, 28, 3, 126

    CrossRef

  16. 16
    S.J. Chueh, B.R. Sankari, R. Gonzales-Chambers, L. Lipscomb, J. Africa, J. Williams, A.M. Jones, Temsirolimus as Base Immunosuppressant for a Recipient With Metastatic Renal Cancer: Adequate Immunosuppression and Oncological Control—Case Report, Transplantation Proceedings, 2014, 46, 1, 271

    CrossRef

  17. 17
    Goran B. Klintmalm, Sammy Saab, Johnny C. Hong, Björn Nashan, The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy, Clinical Transplantation, 2014, 28, 6
  18. 18
    Goran B. Klintmalm, Björn Nashan, The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence, Journal of Transplantation, 2014, 2014, 1

    CrossRef

  19. 19
    Michael Oellerich, Ekkehard Schütz, Philipp Kanzow, Jessica Schmitz, Julia Beck, Otto Kollmar, Frank Streit, Philip D. Walson, Use of Graft-Derived Cell-Free DNA as an Organ Integrity Biomarker to Reexamine Effective Tacrolimus Trough Concentrations After Liver Transplantation, Therapeutic Drug Monitoring, 2014, 36, 2, 136

    CrossRef

  20. 20
    Louise Barbier, Stéphane Garcia, Jérôme Cros, Patrick Borentain, Danielle Botta-Fridlund, Valérie Paradis, Yves-Patrice Le Treut, Jean Hardwigsen, Assessment of chronic rejection in liver graft recipients receiving immunosuppression with low-dose calcineurin inhibitors, Journal of Hepatology, 2013, 59, 6, 1223

    CrossRef

  21. 21
    Narendra S. Choudhary, Sanjiv Saigal, Rajat Shukla, Hardik Kotecha, Neeraj Saraf, Arvinder S. Soin, Current Status of Immunosuppression in Liver Transplantation, Journal of Clinical and Experimental Hepatology, 2013, 3, 2, 150

    CrossRef

  22. 22
    James F. Trotter, Monica Grafals, Angel E. Alsina, Early use of renal-sparing agents in liver transplantation: A closer look, Liver Transplantation, 2013, 19, 8
  23. 23
    Paolo Simone, Faouzi Saliba, Lutz Fischer, End of the Line for Sirolimus in Liver Transplant Recipients With Hepatitis C Virus?, Liver Transplantation, 2013, 19, 2
  24. 24
    H. J. Eisen, J. Kobashigawa, R. C. Starling, D. F. Pauly, A. Kfoury, H. Ross, S.-S. Wang, B. Cantin, A. Van Bakel, G. Ewald, S. Hirt, H. Lehmkuhl, A. Keogh, M. Rinaldi, L. Potena, A. Zuckermann, G. Dong, C. Cornu-Artis, P. Lopez, Everolimus Versus Mycophenolate Mofetil in Heart Transplantation: A Randomized, Multicenter Trial, American Journal of Transplantation, 2013, 13, 5
  25. 25
    Gillian M. Keating, Katherine A. Lyseng-Williamson, Everolimus: A Guide to Its Use in Liver Transplantation, BioDrugs, 2013, 27, 4, 407

    CrossRef

  26. 26
    Michael R. Charlton, How important is acute cellular rejection?, Liver Transplantation, 2013, 19, S2
  27. 27
    Maria-Carlota Londoño, Antoni Rimola, John O’Grady, Alberto Sanchez-Fueyo, Immunosuppression minimization vs. complete drug withdrawal in liver transplantation, Journal of Hepatology, 2013, 59, 4, 872

    CrossRef

  28. You have free access to this content28
    Neil Mehta, Ryutaro Hirose, Immunosuppression: Conventions and controversies, Clinical Liver Disease, 2013, 2, 4
  29. 29
    G. Junge, T. Dumortier, H. Schwende, J. Fung, mTOR Inhibition in Liver Transplantation: How to Dose for Effective/Safe CNI Reduction?, Transplantation Proceedings, 2013, 45, 5, 1979

    CrossRef

  30. 30
    Manuel Rodríguez-Perálvarez, Emmanuel Tsochatzis, María Carmen Naveas, Giulia Pieri, Carmen García-Caparrós, James O’Beirne, Antonio Poyato-González, Gustavo Ferrín-Sánchez, Jose Luis Montero-Álvarez, David Patch, Douglas Thorburn, Javier Briceño, Manuel De la Mata, Andrew Kenneth Burroughs, Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma, Journal of Hepatology, 2013, 59, 6, 1193

    CrossRef

  31. 31
    F. Saliba, P. De Simone, F. Nevens, L. De Carlis, H. J. Metselaar, S. Beckebaum, S. Jonas, D. Sudan, L. Fischer, C. Duvoux, K. D. Chavin, B. Koneru, M. A. Huang, W. C. Chapman, D. Foltys, G. Dong, P. M. Lopez, J. Fung, G. Junge, Renal Function at Two Years in Liver Transplant Patients Receiving Everolimus: Results of a Randomized, Multicenter Study, American Journal of Transplantation, 2013, 13, 7
  32. 32
    V. Ram Peddi, Alexander Wiseman, Kenneth Chavin, Douglas Slakey, Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation, Transplantation Reviews, 2013, 27, 4, 97

    CrossRef

  33. 33
    Masashi Utsumi, Yuzo Umeda, Hiroshi Sadamori, Takeshi Nagasaka, Akinobu Takaki, Hiroaki Matsuda, Susumu Shinoura, Ryuichi Yoshida, Daisuke Nobuoka, Daisuke Satoh, Tomokazu Fuji, Takahito Yagi, Toshiyoshi Fujiwara, Risk factors for acute renal injury in living donor liver transplantation: evaluation of the RIFLE criteria, Transplant International, 2013, 26, 8
  34. 34
    Kenya Yamanaka, Marius Petrulionis, Shibo Lin, Chao Gao, Uwe Galli, Susanne Richter, Susanne Winkler, Philipp Houben, Daniel Schultze, Etsuro Hatano, Peter Schemmer, Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma – systematic review and meta-analysis, Cancer Medicine, 2013, 2, 6
  35. 35
    Adrian Reuben, Drug-induced Liver Disease, 2013,

    CrossRef